garadacimab garadacimab FILED
Drug Profile
ModalityAntibody
RouteSC
Therapy AreaRare Disease
Peak Sales Est$1500M
Formulations[]
Companies
AZN (ORIGINATOR)100%
Mechanism: Factor XIIa inhibitor
Expert: Fully human IgG4 monoclonal antibody that inhibits activated Factor XII, preventing kallikrein-kinin pathway activation and bradykinin generation.
Everyday: Blocks a protein that triggers swelling attacks in hereditary angioedema.
Targets: ["FACTOR XIIA"]
Programs (1)
IndicationStageKey StudyRegional Status
HAEPHASE3CHAPTER-1[]
Notes
Factor XIIa inhibitor for HAE.
Data from Supabase · Updated 2026-03-24